Covid-19 vaccine will be run after questions emerged about an error in its UK research. Pharma firm AstraZeneca which is partnering the university made the admission following reports from the US that its best dosage only worked well in younger people.
Oxford University and pharma giant AstraZeneca announced to much fanfare this week that clinical trials were up to 90% effective.
However the group of trial participants who achieved this success rate had actually been given an initial half dose, a blunder first revealed by the Mirror in June.The trial continued and the main group who were given two full doses only recorded an effectiveness rate of 62%.It has now emerged the smaller group of less than 3,000 out of 24,000 trial participants on.